A covalent KRASG12R inhibitor used as a proof-of-concept for covalent arginine modification, an oral dihydroorotate dehydrogenase inhibitor being developed for acute myelogenous leukemia, and a first-in-class YAP-TEAD protein-protein are some examples of this month's MOTM. In the slide deck, you'll find a compound that has over 1400-fold selectivity for Cathepsin K over other biologically relevant cathepsins and a hydroxylated compound that is more than 1900x more selective than its non-hydroxylated counterpart. Check out all ten minireviews in the slide deck, which covers:
Where are the Molecules of the Month in clinical development?
What's known about differentiation from previous molecules?
Where did the starting points come from?
Industry context, mechanism of action details, and more…
Thanks to reviewers Dennis Koester and Bryan McKibben for their nominations and commentary this month.
